Loading
A phase 1/2 trial of AST-001 in pancreatic ductal adenocarcinoma, run by Ascentawits Pharmaceuticals, Ltd, now recruiting.
A Phase I/II Study of AST-001 in Subjects With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06245330 by Ascentawits Pharmaceuticals, Ltd, with 180 participants planned, started 2022-07-07 and due to reach its primary completion in 2027-08-31. Interventions recorded: AST-001.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Ascentawits Pharmaceuticals and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/